Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada

INTRODUCTION: We estimate the lifetime cost of treatment for moderate/severe symptoms associated with benign prostatic hyperplasia (BPH) in a cohort of Canadian men aged 50 to 59, and we evaluate the costs of 2 daily bioequivalent treatment options: fixed-dose combination (FDC) of dutasteride (0.5 m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sayani, Amyn, Ismaila, Afisi, Walker, Anna, Posnett, John, Laroche, Bruno, Nickel, J. Curtis, Su, Zhen
Format: Artigo
Idioma:Inglês
Publicat: Canadian Medical Association 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896551/
https://ncbi.nlm.nih.gov/pubmed/24454593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.755
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars